Question : BGR-34

Will the Minister of AYURVEDA, YOGA AND NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH) be pleased to state:

(a) whether the Ministry has approved BGR-34, an Ayurvedic drug designed for treatment of diabetes;

(b) if so, the details of its supply and distribution by concerned agencies;

(c) whether clinical trials of the drug have been conducted before its launch and if so, the details thereof;

(d) whether said clinical trials are included/noted in Clinical Trials Registry India and if so, the details thereof;

(e) the details of duration of research on BGR-34, the number of people it has been tested upon, the number of peer reviewed journals which have published studies related to the drug; and

(f) whether a patent for the drug has been acquired by the Government and if so, the details thereof?

Answer given by the minister

ANSWER
THE MINISTER OF STATE (IC) OF THE MINISTRY OF AYURVEDA,
YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY
(SHRI SHRIPAD YESSO NAIK)
(a) to (f): Council of Scientific & Industrial Research (CSIR), through its constituent laboratories namely CSIR-Central Institute of Medicinal & Aromatic Plants (CSIR-CIMAP), Lucknow; and CSIR-National Botanical Research Institute (CSIR-NBRI), Lucknow jointly developed scientifically validated herbal product NBRMAP-DB as anti-diabetic, hypoglycemic formulation with hepato-protective and anti-oxidant properties and the knowhow for the product was licensed to M/s AIMIL Pharma Ltd., Delhi who are manufacturing and marketing it as BGR-34.

Contd…….



-2-

M/s AIMIL Pharmaceuticals, the licensee carried out the clinical study of BGR-34 and the trial was registered in clinical trial registry of India (Registration number: CTRI/2016/11/007476). The Number of people tested was 64.

The research on the technology was initiated in the year 2010 and the technology was transferred in the year 2015. A separate clinical trial has also been registered (CTRI/2017/09/009709 [Registered on: 11/09/2017]) which has been done on 100 patients. Publication on the said formulation is available in public domain. (Preliminary clinical assessment and non- toxicity evaluation of an Ayurveda formulation BGR-34 in NIDDM published in Journal of Traditional and Complementary Medicine, https://doi.org/10.1016/j.jtcme.2017.11.004, In press).
The patents have been filed for the formulation (0097NF2014/IN and 0097NF2014/WO

Download PDF Files